ClinicalTrials.gg
Not yet recruitingNCT05428371THYOMICSUpdated Jun 23, 2022

Assessment the Cancer Risk of Indeterminate Thyroid Nodules Through Integration of Clinical, Ultrasonographic and Multiomic Features

An observational study in Thyroid Nodule and Thyroid Cancer, sponsored by University of Cagliari. Not yet recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-06-23.

Sponsored by University of Cagliari · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
256
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Thyroid Nodule with a site in Italy — 6 open to participants now, 6 under way, none of them phase 3. Thyroid Nodule · Italy.

Started
2023
with 1 other
Observational
4 of 11
4 open now
Registered
5th of 11
by date
Lead sponsor
1 of 11
University of Cagliari

Among the 11 studies in Thyroid Nodule with a site in Italy, this one is one of 2 that started in 2023, is one of 4 observational ones, and was the 5th registered.

Thyroid Nodule

208 studies on the registry are indexed under Thyroid Nodule; 64 are open to participants now.

Browse Thyroid Nodule studies →

Open to participants now

6 of the 11 studies in Thyroid Nodule with a site in Italy are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 43 Thyroid Nodule studies recruiting now, 33 (77%) set no upper age limit and 5 (12%) stop at 75 or younger; 5 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Thyroid Nodule with a site in Italy, or all of them as a file.
02

Study summary

Indeterminate thyroid nodules have a mild risk of malignancy (15-30%). The aim of our study is to individuate new biomarkers of thyroid carcinoma through multiomic analyses of blood samples and of specimen samples of patients with indeterminate thyroid nodules.

03

Conditions studied

  • Thyroid Nodule
  • Thyroid Cancer

Keywords

  • Thyroid carcinoma
  • Indeterminate thyroid nodule
  • Genomics
  • Proteomics
  • Metabolomics
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

We plan to include in our study patients with indeterminate thyroid nodules (Class III and Class IV according to Bethesda classification) who have a mild risk of thyroid cancer (15-30%)

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with indeterminate thyroid nodules (Class III and Class IV according to Bethesda Classification of thyroid nodules)

Exclusion criteria

Exclusion Criteria:

  • Patients with concomitant thyroid nodules of Bethesda Class V or Class VI
  • Patients with preoperative diagnosis of lymph node of central or lateral neck compartment
  • Patients with distant metastases
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
256 participants (estimated)
Patient registry
No

Groups and cohorts

  • Thyroid carcinoma

    Patients with indeterminate thyroid nodule and pathological diagnosis of thyroid carcinoma

    Diagnostic Test: Multiomic analyses of blood and surgical specimens

  • Follicular adenoma

    Patients with indeterminate thyroid nodule and pathological diagnosis of follicular adenoma

    Diagnostic Test: Multiomic analyses of blood and surgical specimens

Interventions

  • Diagnostic testMultiomic analyses of blood and surgical specimens

    The following items will be evaluated: * cell free dna length and integrity * presence or absence of SNPs in cfDNA and in DNA extracted from surgical samples * qualitative and quantitative evaluation of serum and surgical specimens proteome (proteomics)

06

What researchers measure

Primary outcomes

  1. Identification of biomarkers of thyroid carcinoma

    Identification of alterations in cfDNA length and integrity, presence of SNPs in cfDNA, alterations of serum proteome predictive of thyroid carcinoma

    Time frame: 50 months

Secondary outcomes

  1. Elaboration of diagnostic algorithm

    Elanoration of diagnostic algorithm predictive of thyroid carcinoma through integration of clinical, ultrasonographic and multiomic variables able to predict che condition of thyroid cancer in patients with indeterminate thryoid nodules

    Time frame: 60 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided — Individual participant data will be available under reasonable request

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2023; primary completion for May 2027, 52 months later.

Of 38 observational studies under Thyroid Nodule, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 32. This study's planned 52 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2022
First posted
Jun 23, 2022
StartEst.
Jan 1, 2023
Primary completionEst.
May 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Jun 23, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 23, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05428371
Lead sponsor
University of Cagliari
Collaborators
Prof. Pietro Giorgio Calò, Dott. Gian Luigi Canu
Responsible party
Fabio Medas (Associate Professor, University of Cagliari) — Principal investigator
First posted
Jun 23, 2022
Start date
Jan 1, 2023 (estimated)
Primary completion
May 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Jun 23, 2022

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion